Cellectis (CLLS) Change in Working Capital (2015 - 2026)
Cellectis (CLLS) posted quarterly Change in Working Capital of -$19.5 million for Q1 2026, down 195.99% year-over-year from $20.3 million in Q1 2025, and down 151.97% quarter-over-quarter from $37.5 million in Q4 2025.
Cellectis (CLLS) Change in Working Capital (2015 - 2026) Analysis & Trends
Cellectis' Change in Working Capital history runs 12 years deep, the most recent figure standing at -$19.5 million for Q1 2026.
- In Q1 2026, Change in Working Capital fell 195.99% year-over-year to -$19.5 million; the TTM figure through Mar 2026 stood at $28.7 million (up 165.23% YoY), while the FY2025 annual figure was $41.6 million, up 177.5% from the prior year.
- Change in Working Capital for Q1 2026 stood at -$19.5 million, down from $37.5 million in the prior quarter.
- The five-year high for Change in Working Capital was $70.1 million in Q4 2022, with the low at -$22.2 million in Q1 2022.
- The 5-year median for Change in Working Capital is -$16.0 million (2023), against an average of -$4.4 million.
- The sharpest annual moves came in 2024 and 2025: Change in Working Capital plunged 606.61% in 2024, then jumped 426.92% in 2025.
- Cellectis' Change in Working Capital stood at $70.1 million in 2022, then slumped by 94.22% to $4.1 million in 2023, then slumped by 606.61% to -$20.5 million in 2024, then surged by 282.66% to $37.5 million in 2025, then plunged by 151.97% to -$19.5 million in 2026.
- Business Quant data shows CLLS's Change in Working Capital at -$19.5 million in Q1 2026, $37.5 million in Q4 2025, and $17.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Working Capital (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | -19.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.50 Mn |
| Mar 31, 2026 | -19.50 Mn |
| Dec 31, 2025 | 37.52 Mn |
| Dec 31, 2025 | 37.52 Mn |
| Sep 30, 2025 | 16.96 Mn |
| Sep 30, 2025 | 16.96 Mn |
| Jun 30, 2025 | -6.31 Mn |
| Jun 30, 2025 | -6.31 Mn |
| Mar 31, 2025 | -6.59 Mn |
| Mar 31, 2025 | -6.59 Mn |
| Dec 31, 2024 | -20.54 Mn |
| Dec 31, 2024 | -20.54 Mn |
| Sep 30, 2024 | -5.19 Mn |
| Sep 30, 2024 | -5.19 Mn |
| Jun 30, 2024 | -11.65 Mn |
| Jun 30, 2024 | -11.65 Mn |
| Mar 31, 2024 | -16.29 Mn |
| Mar 31, 2024 | -16.29 Mn |
| Dec 31, 2023 | 4.06 Mn |
| Dec 31, 2023 | 4.06 Mn |